Treating the chronic diseases GLP-1s miss, with Laurent Audaly

Many companies have tried to jump into the GLP-1 gold rush with their own versions of the blockbuster obesity drug. Prive Bio, whose CEO Laurent Audaly met with pharmaphorum’s Jonah Comstock last month in San Francisco, is taking a different approach: picking up where GLP-1s leave off to treat residual cardiometabolic diseases.

In this interview conducted at the Demy Colton-Informa Biotech Showcase, Audaly describes the extent of the problem in cardiovascular disease and talks a little bit about how his company is positioning itself to help.

GLP-1s have been incredible therapies, Audaly says, but there’s so much more to do to address residual disease for GLP-1 users, whether through better predictive diagnostics or new data-driven treatment. Check out the full video for more.